138 related articles for article (PubMed ID: 28065979)
21. Pioglitazone for diabetes prevention.
Goldstein MR; Mascitelli L
N Engl J Med; 2011 Jul; 365(2):183; author reply 183-4. PubMed ID: 21751925
[No Abstract] [Full Text] [Related]
22. Pioglitazone Use and Risk of Bladder Cancer--Reply.
Ferrara A; Lewis JD; Habel LA
JAMA; 2015 Dec; 314(23):2568-9. PubMed ID: 26670978
[No Abstract] [Full Text] [Related]
23. No strong association is found between pioglitazone and bladder cancer.
Wise J
BMJ; 2015 Jul; 351():h3934. PubMed ID: 26202496
[No Abstract] [Full Text] [Related]
24. Comment: analyses using time-dependent pioglitazone usage in Cox models may lead to wrong conclusions about its association with cancer.
Yang X; Chan JC
Diabetes Care; 2011 Aug; 34(8):e136; author reply 137. PubMed ID: 21788639
[No Abstract] [Full Text] [Related]
25. Updated Review Confirms Potential Risk of Bladder Cancer with Pioglitazone.
Aschenbrenner DS
Am J Nurs; 2017 Apr; 117(4):25. PubMed ID: 28333739
[No Abstract] [Full Text] [Related]
26. Stay vigilant: a glitazone (pioglitazone) can hide a glitazar!
Hillaire-Buys D; Faillie JL; Montastruc JL; Petit P
Eur J Clin Pharmacol; 2012 Dec; 68(12):1681-3. PubMed ID: 22576730
[No Abstract] [Full Text] [Related]
27. Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis.
He S; Tang YH; Zhao G; Yang X; Wang D; Zhang Y
Tumour Biol; 2014 Mar; 35(3):2095-102. PubMed ID: 24092576
[TBL] [Abstract][Full Text] [Related]
28. Meta-analysis confirms raised risk of bladder cancer from pioglitazone.
Kermode-Scott B
BMJ; 2012 Jul; 345():e4541. PubMed ID: 22763399
[No Abstract] [Full Text] [Related]
29. Pioglitazone--when is a prescription drug safe?
Loke YK; Mattishent K
Nat Rev Urol; 2015 Dec; 12(12):655-6. PubMed ID: 26416647
[No Abstract] [Full Text] [Related]
30. Eight cases of bladder cancer in pioglitazone users from India.
Unnikrishnan R; Sundramoorthy C; Deshpande N; Sarvothaman R; Sahay RK; Mehtalia S; Venkatraman JV; Mohan V
J Assoc Physicians India; 2012 Dec; 60():66. PubMed ID: 23781679
[No Abstract] [Full Text] [Related]
31. Pioglitazone and risk of bladder cancer: clarification of the design of the French study.
Perez AT
Diabetologia; 2013 Jan; 56(1):227. PubMed ID: 23135221
[No Abstract] [Full Text] [Related]
32. Global Versus Indian Perspective of Pioglitazone-induced Adverse Drug Reactions Including Bladder Cancer: A Comparative Retrospective Pharmacovigilance Analysis.
Bhushan S; Ray RS; Prakash J; Singh GN
Clin Ther; 2019 Nov; 41(11):2252-2262. PubMed ID: 31543285
[TBL] [Abstract][Full Text] [Related]
33. Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.
Lewis JD; Habel LA; Quesenberry CP; Strom BL; Peng T; Hedderson MM; Ehrlich SF; Mamtani R; Bilker W; Vaughn DJ; Nessel L; Van Den Eeden SK; Ferrara A
JAMA; 2015 Jul; 314(3):265-77. PubMed ID: 26197187
[TBL] [Abstract][Full Text] [Related]
34. Impact of regulatory spin of pioglitazone on prescription of antidiabetic drugs among physicians in India: A multicentre questionnaire-based observational study.
Goyal A; Singh H; Sehgal VK; Jayanthi CR; Munshi R; Bairy KL; Kumar R; Kaushal S; Kakkar AK; Ambwani S; Goyal C; Mazumdar G; Adhikari A; Das N; Stephy DJ; Thangaraju P; Dhasmana DC; Rehman SU; Chakrabarti A; Bhandare B; Badyal DK; Kaur I; Chandrashekar K; Singh J; Dhamija P; Sarangi SC; Gupta YK
Indian J Med Res; 2017 Oct; 146(4):468-475. PubMed ID: 29434060
[TBL] [Abstract][Full Text] [Related]
35. Pioglitazone use in Australia and the United Kingdom following drug safety advisories on bladder cancer risk: An interrupted time series study.
Kemp-Casey A; Mintzes B; Morrow RL; Dormuth CR; Souverein PC; Roughead EE
Pharmacoepidemiol Drug Saf; 2022 Oct; 31(10):1039-1045. PubMed ID: 35790047
[TBL] [Abstract][Full Text] [Related]
36. Pioglitazone and risk of bladder cancer: clarification of the design of the French study. Reply to Perez AT [letter].
Neumann A; Weill A; Ricordeau P; Fagot JP; Alla F; Allemand H
Diabetologia; 2013 Jan; 56(1):228-9. PubMed ID: 23143195
[No Abstract] [Full Text] [Related]
37. Observational follow-up of the PROactive study: a 6-year update.
Erdmann E; Song E; Spanheimer R; van Troostenburg de Bruyn AR; Perez A
Diabetes Obes Metab; 2014 Jan; 16(1):63-74. PubMed ID: 23859428
[TBL] [Abstract][Full Text] [Related]
38. Pioglitazone use and the risk of bladder cancer.
Kuo HW; Tiao MM; Ho SC; Yang CY
Kaohsiung J Med Sci; 2014 Feb; 30(2):94-7. PubMed ID: 24444539
[TBL] [Abstract][Full Text] [Related]
39. Pioglitazone causing urinary bladder cancer? While waiting for the result of the debate, suggestions for physicians.
Cagiltay E; Tuncel T; Yönem A; Ozdemir G
Eur J Intern Med; 2013 Mar; 24(2):e21-2. PubMed ID: 23267737
[No Abstract] [Full Text] [Related]
40. Pioglitazone use and risk of bladder cancer: population based cohort study.
Tuccori M; Filion KB; Yin H; Yu OH; Platt RW; Azoulay L
BMJ; 2016 Mar; 352():i1541. PubMed ID: 27029385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
